Skip to main content

REPLICACION Y TRANSCRIPCION DEL ADN MITOCONDRIAL COMO MECANISMO CENTRAL DE LA SECUENCIA PATOLOGICA QUE CONDUCE A LA NEURODEGENERACION.

SAF2017-89791-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease

  • Podlesniy, Petar
  • Puigros Serra, Margalida
  • Serra, Nuria
  • Fernández-Santiago, Rubén
  • Ezquerra, Mario
  • Tolosa, Eduardo
  • Trullas, Ramón
Background: Both idiopathic and familial Parkinson's disease are associated with mitochondrial dysfunction. Mitochondria have their own mitochondrial DNA (mtDNA) and previous studies have reported that the release of mtDNA is a biomarker of Parkinson's disease. Methods: We have now investigated the relationship between mtDNA replication, transcription and release in fibroblasts from patients with idiopathic (iPD) and Leucine-rich repeat kinase 2 -associated Parkinson's disease (LRRK2-PD), using Selfie-digital PCR, a method that allows absolute quantification of mtDNA genomes and transcripts. Findings: In comparison with healthy controls, we found that fibroblasts from patients with iPD or LRRK2-PD had a high amount of mitochondrial 7S DNA along with a low mtDNA replication rate that was associated with a reduction of cf-mtDNA release. Accumulation of 7S DNA in iPD and LRRK2-PD fibroblasts was related with an increase in H-strand mtDNA transcription. Interpretation: These results show that 7S DNA accumulation, low mtDNA replication, high H-strand transcription, and low mtDNA release compose a pattern of mtDNA dysfunction shared by both iPD and LRRK2-PD fibroblasts. Moreover, these results suggest that the deregulation of the genetic switch formed by 7SDNA that alternates between mtDNA replication and transcription is a fundamental pathophysiological mechanism in both idiopathic and monogenic Parkinson's disease., This work was supported by grants to Ramon Trullas and Petar Podlesniy from the Ministerio de Ciencia, Innovación y Universidades of Spain (Grant: SAF2017-89791-R) and from the Instituto Carlos III, Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, CIBERNED (Grant: PI2016/06-3).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fragile X-associated tremor/ataxia syndrome: Regional decrease of mitochondrial DNA copy number relates to clinical manifestations

  • Alvarez-Mora, María I.
  • Podlesniy, Petar
  • Gelpi, Ellen
  • Hukema, Renate
  • Madrigal, Irene
  • Pagonabarraga-Mora, Javier
  • Trullas, Ramón
  • Milà, Montserrat
  • Rodríguez-Revenga, Laia
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder that appears in at least one-third of adult carriers of a premutation (55-200 CGG repeats) in the fragile X mental retardation 1 (FMR1) gene. Several studies have shown that mitochondrial dysfunction may play a central role in aging and also in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease as well as in FXTAS. It has been recently proposed that mtDNA copy number, measured by the number of mitochondrial genomes per nuclear genome (diploid), could be a useful biomarker of mitochondrial dysfunction. In order to elucidate the role of mtDNA variation in the pathogenesis of FXTAS, mtDNA copy number was quantified by digital droplet Polymerase chain reaction. In human brain samples, mtDNA levels were measured in the cerebellar vermis, dentate nucleus, parietal and temporal cortex, thalamus, caudate nucleus and hippocampus from a female FXTAS patient, a FMR1 premutation male carrier without FXTAS and from three male controls. The mtDNA copy number was further analyzed using this technology in dermal fibroblasts primary cultures derived from three FXTAS patients and three controls as well as in cortex and cerebellum of a CGG knock in FXTAS mice model. Finally, qPCR was carried out in human blood samples. Results indicate reduced mtDNA copy number in the specific brain region associated with disease progression in FXTAS patients, providing new insights into the role of mitochondrial dysfunction in the pathogenesis of FXTAS., Agència de Gestió d'Ajuts Universitaris i de Recerca, Grant/Award Numbers: 2014SGR603, 2017SGR1134; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Grant/Award Number: PI2016/06; Instituto de Salud Carlos III, Grant/Award Numbers: PI12/00879, PI17/01067; Ministerio de Ciencia e Innovación, Grant/Award Number: SAF2017‐89791‐R
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitotic Slippage and Extranuclear DNA in Cancer Chemoresistance: A Focus on Telomeres

  • Salmina, Kristine
  • Bojko, Agnieszka
  • Inashkina, Inna
  • Staniak, Karolina
  • Dudkowska, Magdalena
  • Podlesniy, Petar
  • Rumnieks, Felikss
  • Vainshelbaum, Ninel, M.
  • Pjanova, Dace
  • Sikora, Ewa
  • Erenpreisa, Jekaterina
Mitotic slippage (MS), the incomplete mitosis that results in a doubled genome in interphase, is a typical response of TP53-mutant tumors resistant to genotoxic therapy. These polyploidized cells display premature senescence and sort the damaged DNA into the cytoplasm. In this study, we explored MS in the MDA-MB-231 cell line treated with doxorubicin (DOX). We found selective release into the cytoplasm of telomere fragments enriched in telomerase reverse transcriptase (hTERT), telomere capping protein TRF2, and DNA double-strand breaks marked by γH2AX, in association with ubiquitin-binding protein SQSTM1/p62. This occurs along with the alternative lengthening of telomeres (ALT) and DNA repair by homologous recombination (HR) in the nuclear promyelocytic leukemia (PML) bodies. The cells in repeated MS cycles activate meiotic genes and display holocentric chromosomes characteristic for inverted meiosis (IM). These giant cells acquire an amoeboid phenotype and finally bud the depolyploidized progeny, restarting the mitotic cycling. We suggest the reversible conversion of the telomerase-driven telomere maintenance into ALT coupled with IM at the sub-telomere breakage sites introduced by meiotic nuclease SPO11. All three MS mechanisms converging at telomeres recapitulate the amoeba-like agamic life-cycle, decreasing the mutagenic load and enabling the recovery of recombined, reduced progeny for return into the mitotic cycle., : This work was supported by a grant from the European Regional Development Fund (ERDF) projects No. 1.1.1.2/VIAA/3/19/463 for K.S., partly from No. 1.1.1.1/18/A/099 for J.E and D.P., partly supported by the Polish National Science Center grant UMO-2015/17/B/NZ3/03531 for E.S., grant from the Ministerio de Ciencia, Innovación y Universidades of Spain (Grant: SAF2017-89791-R) for P.P., and the Natural Sciences PhD Student Scholarship from the University of Latvia Foundation to N.M.V.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease

  • Podlesniy, Petar
  • Llorens, Franc
  • Puigros Serra, Margalida
  • Serra, Nuria
  • Sepúlveda-Falla, Diego
  • Schmidt, Christian B.
  • Hermann, Peter
  • Zerr, Inga
  • Trullas, Ramón
Alzheimer’s type dementia (AD) exhibits clinical heterogeneity, as well as differences in disease progression, as a subset of patients with a clinical diagnosis of AD progresses more rapidly (rpAD) than the typical AD of slow progression (spAD). Previous findings indicate that low cerebrospinal fluid (CSF) content of cell-free mitochondrial DNA (cf-mtDNA) precedes clinical signs of AD. We have now investigated the relationship between cf-mtDNA and other biomarkers of AD to determine whether a particular biomarker profile underlies the different rates of AD progression. We measured the content of cf-mtDNA, beta-amyloid peptide 1–42 (Aβ), total tau protein (t-tau) and phosphorylated tau (p-tau) in the CSF from a cohort of 95 subjects consisting of 49 controls with a neurologic disorder without dementia, 30 patients with a clinical diagnosis of spAD and 16 patients with rpAD. We found that 37% of controls met at least one AD biomarker criteria, while 53% and 44% of subjects with spAD and rpAD, respectively, did not fulfill the two core AD biomarker criteria: high t-tau and low Aβ in CSF. In the whole cohort, patients with spAD, but not with rpAD, showed a statistically significant 44% decrease of cf-mtDNA in CSF compared to control. When the cohort included only subjects selected by Aβ and t-tau biomarker criteria, the spAD group showed a larger decrease of cf-mtDNA (69%), whereas in the rpAD group cf-mtDNA levels remained unaltered. In the whole cohort, the CSF levels of cf-mtDNA correlated positively with Aβ and negatively with p-tau. Moreover, the ratio between cf-mtDNA and p-tau increased the sensitivity and specificity of spAD diagnosis up to 93% and 94%, respectively, in the biomarker-selected cohort. These results show that the content of cf-mtDNA in CSF correlates with the earliest pathological markers of the disease, Aβ and p-tau, but not with the marker of neuronal damage t-tau. Moreover, these findings confirm that low CSF content of cf-mtDNA is a biomarker for the early detection of AD and support the hypothesis that low cf-mtDNA, together with low Aβ and high p-tau, constitute a distinctive CSF biomarker profile that differentiates spAD from other neurological disorders., This work has been funded by the Ministerio de Economia y Competitividad of Spain (Grant: SAF2017-89791-R) and by the Instituto Carlos III (Grant: PI2016/06-3) from Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) to R.T. and P.P.; by the Competence Network for Neurodegenerative Dementia (Kompetenznetzwerk Degenerative Demenzen, KNDD), by the Bundesministerium für Bildung und Forschung (BMBF) and by the Alzheimer-Forschungs-Initiative e.V. (AFI 12851) to I.Z., and by the Instituto Carlos III (grants CP16/00041 and PI19/00144) to F.Ll., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Behavioral sensitization and cellular responses to psychostimulants are reduced in D2R knockout mice.

  • Solís, O.
  • García-Sanz, Patricia
  • Martín, A. B.
  • Granado, Noelia
  • Sanz-Magro, Adrián
  • Podlesniy, Petar
  • Trullas, Ramón
  • Murer, Mario Gustavo
  • Maldonado, Rafael
  • Moratalla, Rosario
Repeated cocaine exposure causes long-lasting neuroadaptations that involve alterations in cellular signaling and gene expression mediated by dopamine in different brain regions, such as the striatum. Previous studies have pointed out to the dopamine D1 receptor as one major player in psychostimulants-induced behavioral, cellular, and molecular changes. However, the role of other dopamine receptors has not been fully characterized. Here we used dopamine D2 receptor knockout (D2−/−) mice to explore the role of D2 receptor (D2R) in behavioral sensitization and its associated gene expression after acute and chronic cocaine and amphetamine administration. We also studied the impact of D2R elimination in D1R-mediated responses. We found that cocaine- and amphetamine-induced behavioral sensitization is deficient in D2−/− mice. The expression of dynorphin, primarily regulated by D1R and a marker of direct-pathway striatal neurons, is attenuated in naïve- and in cocaine- or amphetamine-treated D2−/− mice. Moreover, c-Fos expression observed in D2−/− mice was reduced in acutely but not in chronically treated animals. Interestingly, inactivation of D2R increased c-Fos expression in neurons of the striatopallidal pathway. Finally, elimination of D2R blunted the locomotor and striatal c-Fos response to the full D1 agonist SKF81297. In conclusion, D2R is critical for the development of behavioral sensitization and the associated gene expression, after cocaine administration, and it is required for the locomotor responses promoted by D1R activation., This work was supported by grants from the Spanish Ministries of Innovation, Science and Universities (SAF2016-78207-R and PCIN2015-098 to R. Moratalla, SAF2017-84060-R-AEI/FEDER-UE to R. Maldonado, and SAF2017-89791-R to P. Podlesniy and R. Trullas) and Health, Social Services and Equality (PNSD 2016/033 and CIBERNED CB06/05/0055 to R. Moratalla and RETICS/RTA, RD16/0017 to R.Maldonado.) and from the Ramón Areces Foundation (172275 and OTR02679) to R. Moratalla and ANPCYT (Agency for the Promotion of Science and Technology, Argentina), PICT 2013 1523 and 2015 3687 and by the University of Buenos Aires (UBACYT 2018) to M.G.M. and the Catalan Government (AGAUR, #ICREA Acadèmia-2015 and #2017-SGR-669) to R. Maldonado.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease

  • Roca-Agujetas, Vicente
  • Barbero-Camps, Elisabet
  • Dios, Cristina de
  • Podlesniy, Petar
  • Abadin, Xenia
  • Morales, Albert
  • Marí, Montserrat
  • Trullas, Ramón
  • Colell Riera, Anna
Background: Emerging evidence indicates that impaired mitophagy-mediated clearance of defective mitochondria is a critical event in Alzheimer’s disease (AD) pathogenesis. Amyloid-beta (Aβ) metabolism and the microtubule-associated protein tau have been reported to regulate key components of the mitophagy machinery. However, the mechanisms that lead to mitophagy dysfunction in AD are not fully deciphered. We have previously shown that intraneuronal cholesterol accumulation can disrupt the autophagy flux, resulting in low Aβ clearance. In this study, we examine the impact of neuronal cholesterol changes on mitochondrial removal by autophagy. Methods: Regulation of PINK1-parkin-mediated mitophagy was investigated in conditions of acute (in vitro) and chronic (in vivo) high cholesterol loading using cholesterol-enriched SH-SY5Y cells, cultured primary neurons from transgenic mice overexpressing active SREBF2 (sterol regulatory element binding factor 2), and mice of increasing age that express the amyloid precursor protein with the familial Alzheimer Swedish mutation (Mo/HuAPP695swe) and mutant presenilin 1 (PS1-dE9) together with active SREBF2. Results: In cholesterol-enriched SH-SY5Y cells and cultured primary neurons, high intracellular cholesterol levels stimulated mitochondrial PINK1 accumulation and mitophagosomes formation triggered by Aβ while impairing lysosomal-mediated clearance. Antioxidant recovery of cholesterol-induced mitochondrial glutathione (GSH) depletion prevented mitophagosomes formation indicating mitochondrial ROS involvement. Interestingly, when brain cholesterol accumulated chronically in aged APP-PSEN1-SREBF2 mice the mitophagy flux was affected at the early steps of the pathway, with defective recruitment of the key autophagy receptor optineurin (OPTN). Sustained cholesterol-induced alterations in APP-PSEN1-SREBF2 mice promoted an age-dependent accumulation of OPTN into HDAC6-positive aggresomes, which disappeared after in vivo treatment with GSH ethyl ester (GSHee). The analyses in post-mortem brain tissues from individuals with AD confirmed these findings, showing OPTN in aggresome-like structures that correlated with high mitochondrial cholesterol levels in late AD stages. Conclusions: Our data demonstrate that accumulation of intracellular cholesterol reduces the clearance of defective mitochondria and suggest recovery of the cholesterol homeostasis and the mitochondrial scavenging of ROS as potential therapeutic targets for AD., This work was supported by the Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) under grants: RTI2018–095572-B-100 to A.C., RTI2018–095672-B-I00 to A.M., SAF2017–89791-R to R.T.; Fundació La Marató de TV3 (2014–0930 to A.C.); the Instituto de Salud Carlos III under grant PI19/01410 to M.M.; the Agencia de Gestió d’Ajuts Universitaris i de Recerca, Spain (2017_SGR_177); and the CERCA Programme from the Generalitat de Catalunya, Spain. C.dD. has a FPU fellowship from Ministerio de Ciencia, Innovación y Universidades, Spain. We acknowledge support of the publication fee by the CSIC Open Acess Publication Support Initiative through its Unit of Information Resource for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Familial Alzheimer's disease genen mutations regulate mitochondial DNA replication, transcription and release

  • Puigros Serra, Margalida
  • Pablo-Fontecha, Verónica
  • Reparaz, Andrea
  • Podlesniy, Petar
  • Trullas, Ramón
Trabajo presentado en el 19th National Meeting of the Spanish Society of Neuroscience, celebrado en Lleida (España), del 3 al 5 de noviembre de 2021, Mitochondrial DNA (mtDNA) encodes proteins that are necessary for the production of cellular energy by the mitochondria. In neurons, shortage of this energy due to mitochondrial dysfunction triggers neurodegeneration. In our previous studies, we reported that subjects with pathogenic mutations that cause familial Alzheimer’s disease exhibit low content of cell-free mtDNA (cf-mtDNA) in cerebrospinal fluid (CSF) before the appearance of clinical signs, suggesting that a decrease in the CSF content of cf-mtDNA precedes the clinical signs of dementia. However, the source and the mechanisms of cf-mtDNA release are unclear. Moreover, the molecular mechanisms involved in regulation of mtDNA copy number and release by different genes that cause familiar Alzheimer’s disease are unknown. To explore these questions, we have now investigated the effect of APP-Swe/Ind and PSEN1dE9 mutations on mtDNA replication, transcription and release in SH-SY5Y cell clones that permanently express these mutations. We found that either APP-Swe/Ind or PSEN1d9 gene mutations both reduce mtDNA copy number, the amount of L-strand and H-strand mtDNA transcripts per cell, and the release of cf-mtDNA. In addition, we found that pharmacological inhibition of mitophagy enhances the release of cf-mtDNA in control cells, but not in cell clones expressing APP-Swe/Ind and PSEN1dE9 mutations. These results indicate the presence of an mtDNA quality control system independent of mitophagy that is impaired by APP-Swe/Ind and PSEN1dE9 mutations. Moreover, the present results show that alteration of mtDNA dynamics is a common factor of different pathogenic mutations that cause Alzheimer’s disease., Supported by SAF2017-89791-R, CIBERNED PI2020/09-04 and CIBERNED CB06/05/0050 grants., Peer reviewed